Cargando…
Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series
Background: Dornase alfa (DNase) is the only mucus-degrading agent that has proven efficacy in cystic fibrosis (CF). Few studies have evaluated the effects of DNase on the lung clearance index (LCI). We report the experience of two CF centers in which LCI monitoring was used to evaluate the efficacy...
Autores principales: | Terlizzi, Vito, Parisi, Giuseppe Fabio, Ferrari, Beatrice, Castellani, Chiara, Manti, Sara, Leonardi, Salvatore, Taccetti, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688561/ https://www.ncbi.nlm.nih.gov/pubmed/36360353 http://dx.doi.org/10.3390/children9111625 |
Ejemplares similares
-
Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index
por: Terlizzi, Vito, et al.
Publicado: (2022) -
Dornase alpha use in patients with cystic fibrosis
por: Marostica, Paulo José C.
Publicado: (2013) -
Modulator Therapy in Cystic Fibrosis Patients with cis Variants in F508del Complex Allele: A Short-Term Observational Case Series
por: Terlizzi, Vito, et al.
Publicado: (2022) -
A first-year dornase alfa treatment impact on clinical
parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis
multicenter study
por: Rozov, Tatiana, et al.
Publicado: (2013) -
The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023)